查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1363189

日本 CDMO（合约开发和製造组织）市场规模、份额和趋势分析报告：按产品、工作流程、用途和细分市场进行预测，2023-2030 年

Japan Contract Development And Manufacturing Organization Market Size, Share & Trends Analysis Report By Product (API, Drug Product), By Workflow (Clinical, Commercial), By Application, And Segment Forecasts, 2023 - 2030
出版日期: | 出版商: Grand View Research | 英文 118 Pages | 商品交期: 2-10个工作天内

价格

日本CDMO（合约开发和製造组织）市场成长和趋势：

根据Grand View Research, Inc.最新报告，预计到2030年日本CDMO（合约开发和製造组织）市场规模将达到195亿美元，2023年至2030年年复合成长率为5.9%。

该市场的主要驱动力是合约开发和製造组织（CDMO）为扩大产能而增加投资、日本人口老化和疾病负担增加以及药品製造和开发服务外包，相关成本较低。

COVID-19大流行增加了CDMO市场的需求。即使在大流行期间，日本的一些 CDMO 也希望透过扩大设施来提高其能力。例如，Bushu Pharmaceutical于2020年8月扩建了Misato工厂设施，成为无菌药品和生技药品的专用温控储存设施。同样，2020年7月，CMIC集团在日本新安装了一家新工厂，专门从事抗体医药品的加工开发和GMP製造。国内CDMO的这些配合措施预计将对市场产生正面影响。

市场参与企业继续采取重大策略配合措施，包括设施扩建、联盟、合作伙伴关係、新服务推出和併购。例如，2020年5月，临床供应服务市场的领导者Catalent宣布计划从Teva 工业（爱知县名古屋市）收购临床包装设施。此次收购将创建一个新的临床 GMP 生产和分销基地，以支援临床研究。此外，2022年7月，康泰伦特宣布将在滋贺县建造一条高速泡罩包装线。这将被添加到自动化填充生产设施中。

日本 CDMO（合约开发和製造组织）市场报告亮点：

  • 到 2022 年，API 产品将占据最大的销售份额，达到 81.0%。产品部分分为原料药及医药产品。
  • 按用途，商业细分市场在 2022 年占据最大收益占有率，达到 88.0%。这是由于对仿製药的需求增加，而慢性病的高负担也促进了成长。
  • 预计肿瘤学领域在预测期内的年复合成长率将达到 6.4%，是最快的。这是因为，由于日本癌症患者数量的增加，对新的癌症治疗药物的需求正在增加。
  • 2020年11月，药明康德扩大了其细胞和基因治疗平台提供的服务。该平台能够更快、更可预测地开发、製造和引入细胞和基因疗法。

目录

第1章调查方法与范围

第2章执行摘要

第3章日本CDMO（合约开发与製造组织）市场变数、趋势与范围

  • 市场体系展望
    • 母市场展望
    • 相关/附随市场展望
  • 普及和成长前景图
  • 市场动态
    • 市场驱动因素分析
    • 市场抑制因素分析
  • 日本CDMO（合约开发与製造组织）市场分析工具
    • 产业分析-波特五力分析
    • PESTEL分析

第4章日本CDMO（合约开发和製造组织）：按产品估算和趋势分析

  • 日本的CDMO（合约开发与製造组织）市场：要点
  • 日本 CDMO（合约开发和製造组织）市场：2022 年和 2030 年趋势和市场占有率分析
  • API
    • 2018年至2030年原料药市场预测
    • 类型
    • 合成
    • 药品
    • 製造业
  • 药品
    • 2018年至2030年医药市场预测
    • 口服固态给药
    • 半固体给药
    • 液体给药
    • 其他的

第5章日本CDMO（合约开发与製造组织）：依工作流程进行估算与趋势分析

  • 日本的CDMO（合约开发与製造组织）市场：要点
  • 日本 CDMO（合约开发和製造组织）市场：2022 年和 2030 年趋势和市场占有率分析
  • 临床
  • 商业的

第6章日本 CDMO（合约开发与製造组织）：按用途进行估算和趋势分析

  • 日本的CDMO（合约开发与製造组织）市场：要点
  • 日本 CDMO（合约开发和製造组织）市场：2022 年和 2030 年趋势和市场占有率分析
  • 肿瘤学
  • 荷尔蒙
  • 青光眼
  • 循环系统疾病
  • 糖尿病
  • 其他的

第7章竞争形势

  • 主要市场参与企业的最新趋势和影响分析
  • 市场参与企业分类
Product Code: GVR-4-68039-985-5

Japan Contract Development And Manufacturing Organization Market Growth & Trends:

The Japan contract development and manufacturing organization market size is expected to reach USD 19.5 billion by 2030, registering a CAGR of 5.9% from 2023 to 2030, according to a new report by Grand View Research, Inc.. The main drivers of this market are rising investment by contract development and manufacturing organizations (CDMOs) for capacity expansion, a high geriatric population and growing disease burden in Japan, and low costs associated with outsourcing drug manufacturing and development services.

The COVID-19 pandemic boosted the demand for the CDMO market. Several CDMOs in Japan had tried to improve their capability by expanding their facilities even during the pandemic. For instance, in August 2020, Bushu Pharmaceuticals expanded its facility in the Misato plant in Japan to be dedicated to the storage of temperature-controlled sterile drugs and biologics. Similarly, in July 2020, CMIC Group established a new facility in Japan dedicated to processing development and GMP manufacturing of antibody drugs. Such initiatives by CDMOs in the country are expected to have a positive impact on the market.

The market players are continuously engaging in major strategic initiatives like expanding their facilities, collaborating, partnerships, new service launches, and mergers & acquisitions. For instance, in May 2020, Catalent, a market leader in clinical supply services, announced plans to buy a clinical packaging facility from Teva-Takeda Pharmaceuticals, Nagoya Aichi, Japan. By making this purchase, a new clinical GMP production and distribution hub will be created to assist clinical research. Furthermore, in July 2022, Catalent announced that it would be constructing a high-speed blister packaging line in Shiga, Japan. This will be in addition to its automated fill-and-finish production facility.

Japan Contract Development And Manufacturing Organization Market Report Highlights:

  • The API product segment accounted for the largest revenue share of 81.0% in 2022. The product segment is divided into API and drug product
  • Based on application, the commercial segment dominated with the largest revenue share of 88.0% in 2022. This is due to the rising demand for generic drugs, and the high burden of chronic diseases are some factors contributing to the growth
  • The oncology segment is anticipated to register the fastest CAGR of 6.4% during the forecast period, due to the growing number of cancer cases in the country which is improving the demand for new cancer therapeutics
  • In November 2020, WuXi AppTec expanded its services offered by Cell & Gene Therapy Platform. The platform is now capable of developing, manufacturing, and introducing cell and gene therapies faster and with greater predictability

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Product
    • 1.1.2. Workflow
    • 1.1.3. Application
    • 1.1.4. Regional scope
    • 1.1.5. Estimates and forecast timeline
  • 1.2. Research Methodology
  • 1.3. Information Procurement
    • 1.3.1. Purchased database
    • 1.3.2. GVR's internal database
    • 1.3.3. Secondary sources
    • 1.3.4. Primary research
    • 1.3.5. Details of primary research
  • 1.4. Information or Data Analysis
  • 1.5. Market Formulation & Validation
  • 1.6. Model Details
  • 1.7. List of Secondary Sources
  • 1.8. List of Primary Sources
  • 1.9. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Product
    • 2.2.2. Workflow
    • 2.2.3. Application
    • 2.2.4. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Japan Contract Development and Manufacturing Organization Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Market Dynamics
    • 3.3.1. Market driver analysis
    • 3.3.2. Market restraint analysis
  • 3.4. Japan Contract Development and Manufacturing Organization Market Analysis Tools
    • 3.4.1. Industry Analysis - Porter's
      • 3.4.1.1. Supplier power
      • 3.4.1.2. Buyer power
      • 3.4.1.3. Substitution threat
      • 3.4.1.4. Threat of new entrant
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Technological landscape
      • 3.4.2.3. Economic landscape

Chapter 4. Japan Contract Development and Manufacturing Organization: Product Estimates & Trend Analysis

  • 4.1. Japan Contract Development and Manufacturing Organization Market: Key Takeaways
  • 4.2. Japan Contract Development and Manufacturing Organization Market: Movement & Market Share Analysis, 2022 & 2030
  • 4.3. API
    • 4.3.1. API market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.3.2. Type
      • 4.3.2.1. Type market estimates and forecasts, 2018 to 2030 (USD Million)
      • 4.3.2.2. Traditional active pharmaceutical ingredient (traditional API)
      • 4.3.2.2.1. Traditional active pharmaceutical ingredient (traditional API) market estimates and forecasts, 2018 to 2030 (USD Million)
      • 4.3.2.3. Highly potent active pharmaceutical ingredient (HP-API)
      • 4.3.2.3.1. Highly potent active pharmaceutical ingredient (HP-API) market estimates and forecasts, 2018 to 2030 (USD Million)
      • 4.3.2.4. Antibody drug conjugate (ADC)
      • 4.3.2.4.1. Antibody drug conjugate (ADC) market estimates and forecasts, 2018 to 2030 (USD Million)
      • 4.3.2.5. Others
      • 4.3.2.5.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.3.3. Synthesis
      • 4.3.3.1. Synthesis market estimates and forecasts, 2018 to 2030 (USD Million)
      • 4.3.3.2. Synthetic
      • 4.3.3.2.1. Synthetic market estimates and forecasts, 2018 to 2030 (USD Million)
      • 4.3.3.3. Solid
      • 4.3.3.3.1. Solid market estimates and forecasts, 2018 to 2030 (USD Million)
      • 4.3.3.4. Liquid
      • 4.3.3.4.1. Liquid market estimates and forecasts, 2018 to 2030 (USD Million)
      • 4.3.3.5. Biotech
      • 4.3.3.5.1. Biotech market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.3.4. Drug
      • 4.3.4.1. Drug market estimates and forecasts, 2018 to 2030 (USD Million)
      • 4.3.4.2. Innovative
      • 4.3.4.2.1. Innovative market estimates and forecasts, 2018 to 2030 (USD Million)
      • 4.3.4.3. Generic
      • 4.3.4.3.1. Generic market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.3.5. Manufacturing
      • 4.3.5.1. Manufacturing market estimates and forecasts, 2018 to 2030 (USD Million)
      • 4.3.5.2. Continuous manufacturing
      • 4.3.5.2.1. Continuous manufacturing market estimates and forecasts, 2018 to 2030 (USD Million)
      • 4.3.5.3. Batch manufacturing
      • 4.3.5.3.1. Batch manufacturing market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.4. Drug Product
    • 4.4.1. Drug product market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.4.2. Oral solid dose
      • 4.4.2.1. Oral solid dose market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.4.3. Semi-solid dose
      • 4.4.3.1. Semi-solid dose market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.4.4. Liquid dose
      • 4.4.4.1. Liquid dose market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.4.5. Others
      • 4.4.5.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 5. Japan Contract Development and Manufacturing Organization: Workflow Estimates & Trend Analysis

  • 5.1. Japan Contract Development and Manufacturing Organization Market: Key Takeaways
  • 5.2. Japan Contract Development and Manufacturing Organization Market: Movement & Market Share Analysis, 2022 & 2030
  • 5.3. Clinical
    • 5.3.1. Clinical market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.4. Commercial
    • 5.4.1. Commercial market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 6. Japan Contract Development and Manufacturing Organization: Application Estimates & Trend Analysis

  • 6.1. Japan Contract Development and Manufacturing Organization Market: Key Takeaways
  • 6.2. Japan Contract Development and Manufacturing Organization Market: Movement & Market Share Analysis, 2022 & 2030
  • 6.3. Oncology
    • 6.3.1. Oncology market estimates and forecasts, 2018 to 2030 (USD Million)
  • 6.4. Hormonal
    • 6.4.1. Hormonal market estimates and forecasts, 2018 to 2030 (USD Million)
  • 6.5. Glaucoma
    • 6.5.1. Glaucoma market estimates and forecasts, 2018 to 2030 (USD Million)
  • 6.6. Cardiovascular Disease
    • 6.6.1. Cardiovascular disease market estimates and forecasts, 2018 to 2030 (USD Million)
  • 6.7. Diabetes
    • 6.7.1. Diabetes delivery market estimates and forecasts, 2018 to 2030 (USD Million)
  • 6.8. Others
    • 6.8.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 7.2. Market Participant Categorization
    • 7.2.1. CORDENPHARMA INTERNATIONAL
      • 7.2.1.1. Company overview
      • 7.2.1.2. Financial performance
      • 7.2.1.3. Product benchmarking
      • 7.2.1.4. Strategic initiatives
    • 7.2.2. WuXi AppTec
      • 7.2.2.1. Company overview
      • 7.2.2.2. Financial performance
      • 7.2.2.3. Product benchmarking
      • 7.2.2.4. Strategic initiatives
    • 7.2.3. Cambrex Corporation
      • 7.2.3.1. Company overview
      • 7.2.3.2. Financial performance
      • 7.2.3.3. Product benchmarking
      • 7.2.3.4. Strategic initiatives
    • 7.2.4. Recipharm AB
      • 7.2.4.1. Company overview
      • 7.2.4.2. Financial performance
      • 7.2.4.3. Product benchmarking
      • 7.2.4.4. Strategic initiatives
    • 7.2.5. Lonza
      • 7.2.5.1. Company overview
      • 7.2.5.2. Financial performance
      • 7.2.5.3. Product benchmarking
      • 7.2.5.4. Strategic initiatives
    • 7.2.6. Catalent, Inc.
      • 7.2.6.1. Company overview
      • 7.2.6.2. Financial performance
      • 7.2.6.3. Product benchmarking
      • 7.2.6.4. Strategic initiatives
    • 7.2.7. Laboratory Corporation of America Holdings
      • 7.2.7.1. Company overview
      • 7.2.7.2. Financial performance
      • 7.2.7.3. Product benchmarking
      • 7.2.7.4. Strategic initiatives
    • 7.2.8. Thermo Fisher Scientific, Inc
      • 7.2.8.1. Company overview
      • 7.2.8.2. Financial performance
      • 7.2.8.3. Product benchmarking
      • 7.2.8.4. Strategic initiatives
    • 7.2.9. Samsung BioLogics
      • 7.2.9.1. Company overview
      • 7.2.9.2. Financial performance
      • 7.2.9.3. Product benchmarking
      • 7.2.9.4. Strategic initiatives
    • 7.2.10. FUJIFILM Corporation (FUJIFILM Diosynth Biotechnologies U.S.A.)
      • 7.2.10.1. Company overview
      • 7.2.10.2. Financial performance
      • 7.2.10.3. Product benchmarking
      • 7.2.10.4. Strategic initiatives
    • 7.2.11. SUMITOMO CHEMICAL COMPANY, LIMITED
      • 7.2.11.1. Company overview
      • 7.2.11.2. Financial performance
      • 7.2.11.3. Product benchmarking
      • 7.2.11.4. Strategic initiatives
    • 7.2.12. CMIC HOLDINGS Co., LTD
      • 7.2.12.1. Company overview
      • 7.2.12.2. Financial performance
      • 7.2.12.3. Product benchmarking
      • 7.2.12.4. Strategic initiatives
    • 7.2.13. Bushu Pharmaceuticals LTD.
      • 7.2.13.1. Company overview
      • 7.2.13.2. Financial performance
      • 7.2.13.3. Product benchmarking
      • 7.2.13.4. Strategic initiatives
    • 7.2.14. NIPRO
      • 7.2.14.1. Company overview
      • 7.2.14.2. Financial performance
      • 7.2.14.3. Product benchmarking
      • 7.2.14.4. Strategic initiatives

List of Tables

  • Table 1 List of Abbreviations
  • Table 2 Japan contract development and manufacturing organization market, by product, 2018 - 2030 (USD Million)
  • Table 3 Japan contract development and manufacturing organization market, by workflow, 2018 - 2030 (USD Million)
  • Table 4 Japa contract development and manufacturing organization market, by application, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value-chain-based sizing & forecasting
  • Fig. 6 QFD modeling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 Japan contract development and manufacturing organization: Market outlook
  • Fig. 9 Japan contract development and manufacturing organization: Competitive insights
  • Fig. 10 Parent market outlook
  • Fig. 11 Related/ancillary market outlook
  • Fig. 12 Penetration and growth prospect mapping
  • Fig. 13 Industry value chain analysis
  • Fig. 14 Japan contract development and manufacturing organization market driver impact
  • Fig. 15 Japan contract development and manufacturing organization market restraint impact
  • Fig. 16 Japan contract development and manufacturing organization market strategic initiatives analysis
  • Fig. 17 Japan contract development and manufacturing organization market: Product movement analysis
  • Fig. 18 Japan contract development and manufacturing organization market: Product outlook and key takeaways
  • Fig. 19 API market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 20 Type market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 21 Traditional active pharmaceutical ingredient (traditional API) market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 22 Highly potent active pharmaceutical ingredient (HP-API) market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 23 Antibody drug conjugate (ADC) market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 24 Others market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 25 Synthesis market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 26 Synthetic market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 27 Solid market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 28 Liquid market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 29 Biotech market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 30 Drug market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 31 Innovative market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 32 Generic market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 33 Manufacturing market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 34 Continuous manufacturing market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 35 Batch manufacturing market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 36 Drug product market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 37 Oral solid dose market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 38 Semi-solid dose market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 39 Liquid dose market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 40 Others market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 41 Japan contract development and manufacturing organization market: Workflow movement analysis
  • Fig. 42 Japan contract development and manufacturing organization market: Workflow outlook and key takeaways
  • Fig. 43 Clinical market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 44 Commercial market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 45 Japan contract development and manufacturing organization market: Application movement analysis
  • Fig. 46 Japan contract development and manufacturing organization market: Application outlook and key takeaways
  • Fig. 47 Oncology market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 48 Hormonal market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 49 Glaucoma market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 50 Cardiovascular disease market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 51 Diabetes market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 52 Others market estimates and forecasts, 2018 - 2030 (USD Million)